RESEARCH MONOGRAPH · KDC-MN-365

Roxadustat

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

77/100

First-in-class HIF stabilizer with elegant pharmacology, undermined by inconsistent regulatory reception

Roxadustat is the most clinically advanced of the HIF-prolyl hydroxylase inhibitors, and the pharmacology is genuinely interesting whatever you think about the regulatory trajectory.

Mechanistically, HIF-PHIs work by inhibiting the prolyl hydroxylase enzymes (PHD1, PHD2, PHD3) that normally tag HIF-alpha subunits for von Hippel-Lindau-mediated proteasomal degradation in normoxia. Block the PHDs and HIF-alpha accumulates, transcribes its target genes including EPO, transferrin receptor, hepcidin suppressors, and a network of iron metabolism and erythropoiesis genes. The net effect is increased EPO production from kidney and liver (not just kidney, which matters for CKD), plus improved iron utilization. It's an elegant alternative to recombinant EPO because it engages the endogenous regulatory network rather than overriding it.

The phase 3 program (ROCKIES, ALPS, OLYMPUS, DOLOMITES, SIERRAS, ANDES, multiple thousand-patient trials) is one of the larger CKD anemia development programs ever run. Hemoglobin responses comparable to ESAs, better oral availability obviously, and signals around lipid profile improvements and iron parameters that are mechanism-consistent. Approved in China in 2018, Japan and EU in 2021, but the FDA declined approval in 2021 citing cardiovascular safety concerns. The post-approval data from Japan and elsewhere has been informative.

What's worth flagging is the broader HIF biology question. HIF-alpha drives expression of hundreds of genes, including pro-angiogenic VEGF and some tumor-relevant pathways. The theoretical concern about chronic systemic HIF stabilization promoting tumor growth or progression has shaped the regulatory caution, even though the trial data don't show clear oncogenic signals at observed exposures.

Sourcing is straightforward. Standard small molecule, well-characterized HIF-PHI, the trihydrate form is stable, research-grade material is widely available from vendors and the structure-activity series around roxadustat is well-published.

For research, roxadustat and the related HIF-PHIs (daprodustat, vadadustat, enarodustat, molidustat) are useful probes for HIF pathway biology, iron metabolism research, and the broader hypoxic response network. Plenty of interesting chemistry in this series.

What we dont love is the regulatory inconsistency. Approved in major markets globally but blocked in the US on safety concerns that other regulators didn't share. The signal is genuinely ambiguous and we'll know more as real-world data accumulates.

Evidence: 80
Mechanism: 90
Reliability: 78
Safety: 60
Sourcing: 82
Value: 72
Signal: 75
Staying power: 75

Plain-language summary Intrigue 70 / 100

Roxadustat is a small-molecule alternative to injected EPO for kidney disease anemia. Instead of replacing EPO, it blocks the prolyl hydroxylase enzymes that normally tag the HIF transcription factor for destruction in oxygenated tissue. Stabilizing HIF makes the body think it is hypoxic and triggers endogenous EPO transcription plus genes that improve iron utilization. Approved in China and the EU for chronic kidney disease anemia, but the FDA declined to approve it in 2021 over cardiovascular safety concerns. The HIF-PHI mechanism is genuinely novel and the oral route is a major patient convenience over injected EPO. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Hypoxia-inducible factor prolyl hydroxylase inhibitor

An oral HIF-PHI that stabilizes hypoxia-inducible factor and triggers endogenous EPO production; approved for CKD anemia in China and EU.

Abstract

Roxadustat (FG-4592; N-(((3-hydroxy-1-methyl-7-phenoxy-isoquinolin-4-yl)carbonyl)glycine; CAS 808118-40-3; molecular formula C19H16N2O5; molecular weight 352.34) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed at FibroGen and licensed to AstraZeneca and Astellas. Mechanism: inhibition of HIF prolyl-4-hydroxylases (PHD1, PHD2, PHD3) prevents oxygen-dependent degradation of HIF-alpha subunits; the stabilized HIF complex translocates to the nucleus and transactivates HIF target genes including erythropoietin, transferrin, and ceruloplasmin. The result is increased endogenous EPO production and improved iron utilization. Approved in China (2018), EU (2021), Japan, and other markets for CKD anemia; FDA declined approval in 2021 over cardiovascular safety concerns (slight imbalance in cardiovascular events). Plasma half-life is approximately 12 hours; metabolism is via CYP2C8 and UGTs. Used as the canonical HIF-PHI in renal anemia research.

Mechanism of action

Inhibition of HIF prolyl-4-hydroxylases (PHD1-3); stabilizes HIF-alpha and triggers endogenous EPO transcription. Increased iron utilization through HIF target genes.

Reported research dose ranges

Clinical 70 to 200 mg in the published literature.

References

Provenzano R, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis. JAMA 2019.
Chen N, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019.
Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis 2019.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-365

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Roxadustat

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs